quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 18, 2026

Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%?

View original at finance.yahoo.com
Copart Director Daniel Englander Sells 80,000 Shares for $2.2 Million. Should Investors Sell Too, With the Stock Down 40%? Daniel J. Englander, Director at Copart, Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Daniel J. Englander holds no shares directly; his remaining interest consists of approximately 511,000 shares held indirectly through Ursula Capital Partners, representing a 0.0552% ownership stake in Copart.

    60% confidence
  • The shares were sold in multiple transactions at prices ranging from $27.50 to $27.66, with the reported price of $27.55 reflecting the weighted average of these executions.

    60% confidence
  • Ursula Capital Partners distributed 40,000 shares to its limited partners on July 13, 2026, and Daniel J. Englander was excluded from this distribution.

    60% confidence
  • Copart operates as a global provider of online vehicle auctions with a market capitalization of $25.5 billion as of the July 14, 2026 market close, generating $4.6 billion in trailing twelve-month revenue and $1.6 billion in net income over the same period.

    60% confidence
  • Daniel J. Englander sold 80,000 shares of Copart common stock on July 13, 2026, for a transaction value of $2.2 million.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com